RxDoctor Payments Data

Zenna Bell

Adult Health · Windsor, CTNPI 1639668221

Payments from drug & device makers

$3,746in general payments, 2019–2025

Across 82 payments — averaging $45.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$895
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$795
  • Neurocrine Biosciences, Inc.$407
  • Teva Pharmaceuticals USA, Inc.$327
  • Johnson & Johnson$262
  • Otsuka America Pharmaceutical, Inc.$247
  • plus $812 from 7 others

What the payments were for

  • Food & beverage$3,746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,746 in reported general payments places this provider in the 85th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$73,309
Medicare patients
72
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole14$20,156
TrintellixVortioxetine Hydrobromide15$7,115
Ramelteon20$3,109
Memantine Hcl ErMemantine Hcl25$1,957
Mirtazapine51$1,919
Trazodone Hcl151$1,901
Sertraline Hcl138$1,773
Donepezil Hcl62$1,493
Memantine Hcl60$1,389
Olanzapine20$874
Escitalopram Oxalate46$816
Aripiprazole13$755
Bupropion XlBupropion Hcl15$703
Risperidone36$580
Lorazepam36$554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$247$20,15614 claims
Lilly USA, LLCOlanzapine$30$87420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 418 adult health providers in Connecticut.

Other adult health in Windsor

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →